New drug combo takes on advanced cancers in first human trial
NCT ID NCT06868199
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called LM-168, alone or with the immunotherapy toripalimab, in 87 adults with advanced solid tumours that have not responded to standard treatments. The study first checks safety and the right dose, then looks for signs that the tumours shrink. It is a first-in-human study, so the main goals are safety and tolerability, not yet a proven treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LM-168 (a new drug) and toripalimab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 87 participants. The drug may not be effective or could cause unexpected side effects. Success in this small study does not guarantee broader benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bayview Health-Investigational Drug Services
RECRUITINGPerth, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Care Wollongong Pty Limited
RECRUITINGWollongong, New South Wales, Australia
Contact Email: •••••@•••••
-
MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy
RECRUITINGRyde, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University
RECRUITINGRyde, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
One Clinical Reasearch
RECRUITINGPerth, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••